Verition Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

Verition Fund Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41M	Sell	40,000 -15,000	-27%	-$833K	0.01%	1013
2026 Q1	$3.2M	Sell	55,000 -38,756	-41%	-$1.79M	0.02%	769
2025 Q4	$4.2M	Buy	93,756 +36,639	+64%	+$1.54M	0.02%	1006
2025 Q3	$2.29M	Buy	+57,117	New	+$2.01M	0.01%	1856
2025 Q2	–	Sell	-12,508	Closed	-$420K	–	3904
2025 Q1	$420K	Buy	12,508 +4,211	+51%	+$160K	﹤0.01%	2689
2024 Q4	$325K	Buy	+8,297	New	+$343K	﹤0.01%	2739

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Verition Fund Management's XENE Position: Q2 2026 in Review

Verition Fund Management reduced its Xenon Pharmaceuticals (XENE) stake by 27% in Q2 2026, selling an estimated $833K and leaving 40,000 shares worth $2.41M. The position accounts for 0.01% of the portfolio, ranked #1013.

Verition Fund Management first reported a position in XENE in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.2M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Verition Fund Management held 40,000 shares of Xenon Pharmaceuticals worth $2.41M as of Q2 2026.
Verition Fund Management sold 15,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $833K.
Xenon Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1013 holding.
Verition Fund Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Verition Fund Management's Xenon Pharmaceuticals position peaked at $4.2M in Q4 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.